Articles: disease.
-
Randomized Controlled Trial Multicenter Study
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy. ⋯ Adjuvant therapy with durvalumab led to significantly longer overall survival and progression-free survival than placebo among patients with limited-stage small-cell lung cancer. (Funded by AstraZeneca; ADRIATIC ClinicalTrials.gov number, NCT03703297.).
-
According to reports, coronavirus disease 2019 (COVID-19) is associated with various complications, including hematological abnormalities. Lymphopenia and thrombocytopenia have been recognized as common hematological abnormalities. Moreover, some reports have shown cases of neutropenia occurring during or after infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). ⋯ This will allow for effective therapeutic intervention and appropriate disease management in challenging conditions. In this study, our aim was to conduct a comprehensive review of the current literature on neutropenia during or after SARS-CoV2 infection. Furthermore, we assessed whether there have been any documented cases of immune-mediated neutropenia following COVID-19 and if the appropriate laboratory investigations have been carried out in these patients.
-
Veterans Health Administration (VHA) enrollees may use community hospitals for inpatient care and sometimes require transfer to larger community or VHA hospitals. Little is known about interhospital transfer patterns among veterans using community and VHA hospitals or how coronavirus disease 2019 (COVID-19) case surges affected transfer. ⋯ Interhospital transfer was common for veterans with AMI and AIS, especially among rural veterans. Few transfers were to VHA hospitals. COVID-19 case surges were associated with decreased transfer for veterans with AMI, potentially limiting access to needed care.
-
According to current evidence, every 10th to 11th adult with chronic kidney disease (CKD) has a monogenic disease of the kidney. ⋯ Awareness of the high prevalence of monogenic kidney diseases in adults with CKD and alertness to their suggestive clinical features are crucial for the timely initiation of targeted diagnostic testing. The molecular genetic identification of these diseases is a prerequisite for appropriate patient management.